Book Value per Share: Grace Therapeutics, Inc. (GRCE)

Grace Therapeutics (GRCE) - corporate logo

Grace Therapeutics, Inc. (GRCE) develops injectable systems for the therapy of rare brain pathologies, focusing on overcoming the blood-brain barrier. The equity per share trend demonstrates the current balance of resources, while the value of 2.96 reflects this status. High costs for specialized medical logistics are offset by patent protection and exclusive FDA status, which blocks generics from entering the market.

Grace Tx (GRCE) Equity per Share: for the period 10/29/2024 - 10/28/2026

Grace Therapeutics Inc - analytical breakdowns and key metrics (GRCE)

- price and consensus price forecast:
Stock Price Grace Tx|GRCE - Consensus Target
- market capitalization data:
Market Capitalization Grace Therapeutics, Inc.|GRCE - Total Enterprise Value
- book capitalization data:
Net Assets per Single Share Grace Therapeutics|GRCE - Accounting Capitalization|Market Capitalization to Book Value Ratio gracetx.com|GRCE - Company Assets
- debt and liquidity data:
Total Debt to Equity Ratio Grace Therapeutics, Inc.|GRCE - Long-Term Debt to Capital|Short-Term Debt to Equity Grace Tx|GRCE - Aggregate Debt Obligations|Debt to Book Capitalization Ratio Grace Therapeutics, Inc.|GRCE - Long-Term Debt|Company Short-Term Debts Grace Therapeutics
Fundamental company valuation:gracetx.com, GRCE
Manufactured products of Grace Tx

Grace Therapeutics, Inc. (GRCE) minimizes capital expenditures by outsourcing drug development to external laboratories, which directly impacts its equity structure. This metric calculates the net assets per share, allowing for an assessment of the business's intrinsic value and the determination of the investment's margin of safety through an analysis of the current book value per share.

Competitors of Grace Therapeutics, Inc. (GRCE)

BIIB: Book Value per Share|NBIX - Accounting Value per Share|Book Value per Share RGC|AXSM (axsome.com) - Net Asset Value per Share|Net Assets per Single Share ACADIA Pharmaceuticals Inc. (ACAD)|Equity per Share Xenon Pharmaceuticals Inc.|Viking Pharma - Book Value per Share|Net Asset Value per Share Supernus Corp SUPN|Accounting Value per Share CPRX (Catalyst Pharmaceuticals)|denalitherapeutics.com - Book Value per Share|Net Assets per Single Share Harmony Biosciences Holdings, Inc. (HRMY)|BHVN: Accounting Value of a Share|Net Assets per Single Share AMLX|Trevi Corp (TRVI) - Net Asset Value per Share|Praxis Precision Medicines - Book Value per Share|Book Value of One Share AVXL|CeriBell (CBLL) - Net Assets per Single Share|Accounting Value of a Share Prothena Corporation (PRTA)|Book Value per Share ALEC (Alector)|Book Value per Share Annexon Biosciences Inc. ANNX|OMER: Book Value per Share|NGNE - Accounting Value per Share|Book Value per Share ACIU|Net Asset Value per Share Voyager Therapeutics Inc|NMRA - Accounting Value per Share|Accounting Value of a Share Scilex Holding Company, Inc. (SCLX)|Accounting Value per Share Tevogen Bio Holdings|Book Price of a Share alphacognition.com (ACOG)|Book Value per Share Cognition Therapeutics|Accounting Value of a Share Inhibikase Therapeutics Inc IKT|SAVA (Cassava) - Book Value per Share|ASRT: Net Asset Value per Share|Net Assets per Single Share coyatherapeutics.com COYA|Vistagen (VTGN) - Accounting Value of a Share|OVID (Ovid Therapeutics Inc) - Book Value per Share|Book Value per Share ABOS|CRVO - Net Assets per Single Share|Share Book Value alteritytherapeutics.com (ATHE)|CLNN: Book Value per Share|PEPG - Net Asset Value per Share|Jupiter Neurosciences Inc - Accounting Value per Share|Relmada Therapeutics Inc (RLMD) - Book Value per Share|ANVS - Accounting Value per Share|Firefly Neuro (AIFF) - Book Price of a Share|KLTO: Book Value per Share|Net Assets per Share NeuroSense Therapeutics, Ltd.|Book Value per Share RVPH (Reviva Pharmaceuticals Holdings, Inc.)|Accounting Value per Share MTVA (metaviatx.com)|Net Assets per Single Share NRXS|HSDT - Net Assets per Share|Accounting Value per Share Passage Bio Corp (PASG)|NEUP - Accounting Value of a Share|Minerva Neurosciences, Inc. - Book Value per Share|ATHA (Athira Pharma Inc) - Net Assets per Share|Net Assets per Single Share Addex Therapeutics, Ltd. (ADXN)|Equity per Share Alzamend|Book Value per Share CYCN (Cyclerion Therapeutics)|Accounting Value per Share protagenic.com PTIX|Accounting Value per Share KTTA|Net Assets per Share Cortigent Inc CRGT|Book Value per Share ATXI|BCLI: Book Value of One Share|Net Assets per Single Share Cara Therapeutics, Inc. CARA|chromocell.com (CHRO) - Accounting Value of a Share|Book Value per Share ELYM|Accounting Value per Share Intra-Cellular|Longboard Pharma - Book Value per Share|Net Asset Value per Share MRNS (Marinus Pharma)|NKGN - Net Assets per Single Share|Equity per Share neurobopharma.com NRBO|SAGE (Sage Therapeutics) - Book Value per Share|Synaptogenix Inc. (SNPX) - Net Asset Value per Share|TRVN: Accounting Value per Share|VIGL (Vigil Neuroscience, Inc.) - Book Value per Share|WENA - Net Assets per Single Share|Accounting Value of a Share CERE